Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application
05/11/2020 14:09
Nov 5 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT
APPLICATION
COVERING METHODS OF TREATING GOUT, INFLAMMATORY BOWEL DISEASE,
CROHN’S DISEASE, AND ULCERATIVE COLITIS WITH ALLOCETRA
IMMUNOTHERAPY
Source text for Eikon: ID:nGNX619rn1
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment